{"orpha":2103,"name":"Guillain-Barré syndrome","type":"Clinical group","group":"Group of disorders","status":"active","flags":[],"synonyms":["GBS","Guillain-Barré-Strohl syndrome"],"definition":"A clinically heterogeneous spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS) and some other regional variants.","note":null,"url":"https://raremap.alftech.space/d/ORPHA-2103/","orphanet_url":"https://www.orpha.net/en/disease/detail/2103","names":{"fr":{"name":"Syndrome de Guillain-Barré","synonyms":["SGB","Syndrome de Guillain-Barré-Strohl"],"definition":"Le syndrome de Guillain-Barré (SGB) est le terme utilisé pour décrire un spectre de neuropathies post-infectieuses rares qui surviennent en général chez des sujets jusque là en bonne santé. Le spectre clinique du SGB est hétérogène et comprend la polyradiculonévrite démyélinisante inflammatoire aiguë (PDIA), deux neuropathies axonales, dont une forme motrice pure (neuropathie axonale motrice aiguë, AMAN), et une forme sensitivo-motrice (neuropathie axonale sensitivo-motrice aiguë, AMSAN), le syndrome de Miller-Fisher et quelques autres variantes régionales."},"de":{"name":"Guillain-Barré-Syndrom","synonyms":["GBS","Guillain-Barré-Strohl-Syndrom"],"definition":"Der Terminus Guillain-Barré-Syndrom (GBS) beschreibt ein Spektrum von seltenen postinfektiösen Neuropathien, die bei sonst gesunden Personen auftreten. Das klinische Spektrum des GBS ist heterogen und umfaßt eine akute entzündliche demyelinisierende Polyneuropathie (AIDP), eine akute motorische axonale Neuropathie (AMAN), eine akute motorische und sensorische axonale Neuropathie (AMSAN), das Miller-Fisher-Syndrom (MFS ; s. diese Termini) und einige andere, regionale Varianten."},"es":{"name":"Síndrome de Guillain-Barré","synonyms":["GBS","SGB","Síndrome de Guillain-Barré-Strohl"],"definition":"Es un espectro clínicamente heterogéneo de neuropatías post-infecciosas poco frecuentes que aparecen en pacientes que, por lo demás, presentan un buen estado de salud y comprende la polirradiculoneuropatía desmielinizante inflamatoria aguda (AIDP), la neuropatía axonal aguda motora (AMAN), la neuropatía sensitivo-motora axonal aguda (AMSAN), el síndrome de Miller-Fisher (SMF) y otras variantes regionales."},"it":{"name":"Sindrome di Guillain-Barré","synonyms":["GBS","Sindrome di Guillain-Barre","Sindrome di Guillain-Barré-Strohl"]},"nl":{"name":"Syndroom van Guillain-Barré","synonyms":["GBS","Syndroom van Guillain-Barré-Strohl"],"definition":"Een klinisch heterogeen spectrum van zeldzame postinfectieuze neuropathieën die meestal voorkomen bij voor het overige gezonde patiënten, waaronder acute inflammatoire demyeliniserende polyradiculoneuropathie (AIDP), acute motorische axonale neuropathie (AMAN) en acute motorisch-sensorische axonale neuropathie (AMSAN), syndroom van Miller-Fisher (MFS) en enkele andere regionale varianten."},"pt":{"name":"Síndrome Guillain-Barré","definition":"Espectro clinicamente heterógeneo de neuropatias pós-infeciosas raras que ocorrem geralmente em indivíduos previamente saudáveis e que abrange a polirradiculoneuropatia desmielinizante inflamatória aguda (AIDP), a neuropatia axonal motora aguda (AMAN) e a neuropatia axonal motora e sensitiva aguda (AMSAN), a síndrome de Miller-Fisher (MFS) e algumas outras variantes regionais."},"pl":{"name":"Zespół Guillaina i Barrégo","synonyms":["GBS","Zespół Guillaina, Barrégo i Strohla"]},"cs":{"name":"Guillainův-Barrého syndrom","synonyms":["GBS","AIDP","Guillainův-Barrého-Strohlův syndrom","Landryho-Guillainův-Barrého syndrom","Guillain-Barrého syndrom","Guillain-Barrého-Strohlův syndrom","Landry-Guillain-Barrého syndrom"]},"uk":{"name":"Синдром Гієна-Барре","synonyms":["GBS","Синдром Гійєна-Барре-Строля"],"definition":"A clinically heterogeneous spectrum of rare post-infectious neuropathies that usually occur in otherwise healthy patients and encompasses acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), Miller-Fisher syndrome (MFS) and some other regional variants."},"zh":{"name":"吉兰巴雷综合征","synonyms":["Guillain-Barré-Strohl综合征"]},"tr":{"name":"Guillain-Barre sendromu","synonyms":["GBS","Guillain-Barré-Strohl sendromu"]}},"xrefs":[{"source":"ICD-10","code":"G61.0","qualifier":"E","icd_relation":"specific","validated":true},{"source":"ICD-11","code":"8C01.0","qualifier":"NTBT","icd_relation":"index","validated":true,"icd11_uri":"1196874419"},{"source":"MONDO","code":"0016218","qualifier":"E","icd_relation":null,"validated":true},{"source":"MONDO","code":"16218","qualifier":"E","icd_relation":null,"validated":true},{"source":"MeSH","code":"D020275","qualifier":"E","icd_relation":null,"validated":true},{"source":"UMLS","code":"C0018378","qualifier":"E","icd_relation":null,"validated":true},{"source":"GARD","code":"6554","qualifier":"E","icd_relation":null,"validated":true},{"source":"MedDRA","code":"10018767","qualifier":"E","icd_relation":null,"validated":true}],"associations":[],"incoming_associations":[],"preferential_parent":{"orpha":98006,"name":"Rare neurologic disease"},"parents":[{"orpha":207038,"name":"Acute and subacute inflammatory demyelinating polyneuropathy","classifications":[181]},{"orpha":182064,"name":"Rare neuroinflammatory or neuroimmunological disease","classifications":[181]}],"children":[{"orpha":98916,"name":"Acute inflammatory demyelinating polyradiculoneuropathy","type":"Disease"},{"orpha":98917,"name":"Acute motor and sensory axonal neuropathy","type":"Disease"},{"orpha":98918,"name":"Acute motor axonal neuropathy","type":"Disease"},{"orpha":231413,"name":"Variant of Guillain-Barré syndrome","type":"Category"}],"genes":[],"genes_via_subtypes":[],"inheritance":["Multigenic/multifactorial"],"onset":["All ages"],"prevalence":[{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.45,"area":"Worldwide","status":"Validated","source":"19088488[PMID]_[EXPERT]_ ORPHANET"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.72,"area":"United States","status":"Validated","source":"22846726[PMID]"},{"type":"Point prevalence","qualification":"Value and class","class":"1-9 / 100 000","value":3.5,"area":"Europe","status":"Validated","source":"[EXPERT]_European Medicines Agency 2007[OTHER]_ ORPHANET"},{"type":"Point prevalence","qualification":"Value and class","class":"1-5 / 10 000","value":25.0,"area":"Denmark","status":"Validated","source":"20066507[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":1.4,"area":"Europe","status":"Not yet validated","source":"22694000[PMID]_ORPHANET"},{"type":"Point prevalence","qualification":"Value and class","class":"1-5 / 10 000","value":12.0,"area":"Egypt","status":"Validated","source":"23146298[PMID]"},{"type":"Annual incidence","qualification":"Value and class","class":"1-9 / 100 000","value":2.42,"area":"France","status":"Validated","source":"27991707[PMID]"}],"phenotypes":null}